Recognizing the fact that some models of ADCC may not reflect triggering exclusively through CD16 and because of the requirement of NKG2D to achieve optimal levels of antibody-dependent cytolysis in our model33, we also tested an additional model of ADCC using the murine mastocytoma cell line P815, coated with monoclonal anti-human FCγRIIIa to discriminate signaling through CD16 (supplementary data 3). This evidence concerns the gene FCGR3A and mastocytoma.